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Table. Thirty-Day and One-Year Outcomes
Thirty-Day
Outcomes
Excess Dose
(N¼543)
Recommended
Dose (N¼4,744) HR [95%CI] p-Value
All-cause death 17 (3.1) 56 (1.2) 2.70
[1.59, 4.76]
0.0002
Reinfarction 39 (7.3) 301 (6.4) 1.15
[0.83, 1.61]
0.41
Stent thrombosis
(def/prob)
16 (3.0) 79 (1.7) 1.82
[1.06, 3.13]
0.03
Non-CABG major
bleeding
69 (12.8) 329 (7.0) 1.89
[1.47, 2.44]
<0.0001
MACE 57 (10.5) 399 (8.5) 1.27
[0.96, 1.69]
0.09
NACE 106 (19.6) 650 (13.8) 1.49
[1.20, 1.82]
<0.0001
One-Year Outcomes
All-cause death 40 (7.5) 148 (3.7) 2.44
[1.72, 3.45]
<0.0001
Reinfarction 62 (11.8) 415 (9.1) 1.33
[1.03, 1.75]
0.03
Stent thrombosis
(def/prob)
18 (3.4) 113 (2.6) 1.45
[0.88, 2.38]
0.15
MACE 114 (21.3) 772 (17.3) 1.33
[1.10, 1.61]
0.004
Values presented as n (%). MACE¼Major Adverse Cardiovascular Events (death, myocardial
infarction unplanned revascularization for ischemia, stroke); NACE¼Net Adverse Clinical
Events (MACE or major bleeding).
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Background: With the widespread use of high loading dose of clopidogrel or new
P2Y12 receptor inhibitors, limited data are available regarding the efﬁcacy and safety
of the administration of a glycoprotein IIb/IIIa inhibitor to patients with ST-segment
elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary
intervention (PPCI). Thus, we analyzed the short-term results of abciximab admin-
istration to a contemporary cohort of STEMI patients undergoing PPCI.
Methods: Between July-2012 and April-2014, 482 STEMI patients underwent PPCI
in a tertiary care hospital. All patients were preloaded with aspirin and a thienopir-
idine. 94% of the patients were treated with unfractioned heparin and 6% with
bivalirudin. PPCI was performed via transradial approach in 84% of cases. We
compared the clinical characteristics and the 30-day outcome between 2 groups of
patients: those treated with abciximab (group A, n¼287) and those treated without
(group B, n¼195).
Results: Patients in group A were younger, more frequently men, had more body
weight, hypertension, multivessel disease and thrombus burden than patients in group
B. Preloading with clopidogrel (group A: 78% vs group B: 73%, p¼0.2) and/or with a
new P2Y12 receptor inhibitor (group A: 30% vs. group B: 38%, p¼0.1) was similar in
both groups. At 30 days, the efﬁcacy endpoint (composite of death, reinfarction, new
target-vessel revascularization or ischemic stroke) was observed less frequently in
group A than in group B (5.5% vs. 11.7%, respectively, p¼0.02), while the safety
endpoint (BARC type 3 bleeding) occurred similarly in both groups of patients
(group A: 4.1% vs. group B: 3.5%, p¼0.7). The net adverse clinical event rate
(combination of the efﬁcacy and safety endpoints) was also similar in both groups of
patients (group A: 9.7%vs. group B: 15.3%, p¼0.06).
Conclusions: In contemporary PPCI, administration of abciximab to selected patients
appears safe and effective, and is potentially associated with a reduction in adverse
ischemic event rate, without an increase in major bleeding risk.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/PhaPharmacotherapy - Chronic anticoagulants
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Acute Coronary Syndromes: The AVIATOR Registry
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Background: Current guidelines recommend dual antiplatelet therapy (DAPT) in
patients with acute coronary syndrome (ACS) treated with percutaneous coronary
intervention (PCI) and anticoagulation for stroke protection in patients with atrial
ﬁbrillation (AF) and CHADS2 scores 2, but optimum antithrombotic therapy in
patients with AF undergoing PCI for ACS remains controversial.
Methods: Among 859 consecutive patients with AF treated with PCI in the AVIA-
TOR (Antithrombotic strategy Variability InATrial ﬁbrillation and Obstructive coro-
nary disease Revascularized with PCI) registry, 425 presented with ACS. Patients
were stratiﬁed according to medications at discharge: triple therapy (TT; warfarin +
DAPT) or DAPT (aspirin + clopidogrel). Major adverse cardiovascular events
(MACE; death, myocardial infarction, stroke) and clinically relevant bleeding (BARC
2) were compared between groups over 1 year.
Results: Mean age was similar in the 2 groups (74  9 years). Patients receiving TT
(n¼185, 43.5%) were more often male with higher ejection fraction and more likely to
receive bare metal stents than patients discharged on DAPT (n¼240, 56.5%). The
1-year incidence of MACE was similar in the TT vs. DAPT groups (14 vs. 16%,
adjusted HR 0.9; p¼0.78) but patients on TT more often developed bleeding (13 vs.
6%, adjusted HR 2.05 p¼0.03; Figure).
Conclusions: DAPT was more often prescribed in these patients with AF and
CHADS2 scores 2 undergoing PCI for ACS. Compared to patients on DAPT, those
given TT had similar 1-year rates of MACE but more bleeding.TCT-475
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Background: Optimal antithrombotic regimen for patients with atrial ﬁbrillation (AF) un-
dergoing drug-eluting stent (DES) implantation for complex coronary artery disease is un-
certain.Theaimof study is to compare thenet clinical outcomesbetween triple antithrombotic
therapy group (TAT; aspirin, thienopyridine and warfarin) and dual antiplatelet therapy
group (DAPT; aspirin and thienopyridine) in AF patients undergoing DES implantation.
Methods: Among a total of 367 AF patients undergoing DES implantation, 154 pa-
tients (42.0%) received TAT and 213 patients (58.0%) received DAPT. The prescribedrmacotherapy - Chronic anticoagulants (warfarin and newer agents) B139
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years). The primary end point was deﬁned as net clinical outcomes, a composite of
major bleeding and major adverse cardiac and cerebral events (MACCE). Propensity
score-matching analysis was also performed in 99 patient pairs.
Results: The net clinical outcomes of the TAT group was worse than the DAPT group
(34.3% v 21.1%, p¼0.006), which was mainly driven by higher incidence of major
bleeding (16.7% vs 4.6%, p< 0.001), without any signiﬁcant increase in MACCE
(22.1% vs 17.7%, p¼0.313). In multivariate analysis, the TAT was an independent
predictor for worse net clinical outcomes (HR 1.67; 95% CI 1.09-2.57; p¼0.018) and
major bleeding (HR 3.74; 95% CI 1.74-8.02; p¼0.001). After propensity score-
matching, TAT group still had worse net clinical outcomes, mainly driven by higher
major bleeding, than DAPT group.
Conclusions: In AF patients undergoing DES implantation, prolonged administration
of TAT is associated with worse net clinical outcomes due to the substantial increase
in major bleeding without any improvement of MACCE.
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Background: Chronic kidney disease (CKD) confers increased risk for bleeding
and ischemic complications after percutaneous coronary intervention (PCI).
Guidelines recommend dual antiplatelet therapy (DAPT) in patients undergoing PCI
and anticoagulation in patients with atrial ﬁbrillation (AF) and CHADS2 scores2.
The optimal antithrombotic therapy in patients with CKD and AF after PCI is
unknown.
Methods: The AVIATOR (Antithrombotic strategy Variability In ATrial ﬁbrillation
and Obstructive coronary disease Revascularized with PCI) registry, included 859
consecutive patients with AF treated with PCI, of whom 286 had CKD (e-GFR< 60
ml/min).CKD patients were stratiﬁed in 2 groups; triple therapy (TT; warfarin plus
DAPT) or DAPT (aspirin plus clopidogrel. Major adverse cardiovascular events
(MACE) and clinically relevant bleeding (BARC2) were compared between the
groups at one year.
Results: Mean age was similar in the 2 groups (769 years). Patients receiving
TT (n¼127, 44.4%) were more often male and had higher ejection fraction
compared to patients discharged on DAPT (n¼159, 55.6%). Mean CHADS2
scores were identical between groups (3.11). MACE incidence at 1-year was
similar in the TT vs. DAPT groups (20 vs. 11%, p¼0.54) but patients on TT
tended to bleed more often (15 vs. 7%, p¼0.04). However, after adjusting for
confounding factors the association of TT with increased bleeding was attenu-
ated. (Figure)Conclusions: The most commonly prescribed regimen in these high risk patients with
CKD and AF undergoing PCI is DAPT. Patients on TT had similar rates of 1-year
MACE but more bleeding compared to those given DAPT.B140 JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT AbstTCT-477
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Background: Elderly patients with atrial ﬁbrillation (AF) undergoing percutaneous
coronary intervention (PCI) are at an increased risk for bleeding and ischemic com-
plications. Optimum antithrombotic therapy in this group is controversial and
challenging.
Methods: Among 859 patients from the AVIATOR (Antithrombotic strategy vari-
ability in AF and obstructive coronary disease) registry who underwent PCI, 387
patients with age  75 were selected for this analysis. At discharge, these patients
were stratiﬁed into two groups: those receiving dual antiplatelet therapy (DAPT;
aspirin plus clopidogrel), and those receiving triple therapy (TT; DAPT plus warfarin).
Major adverse cardiovascular events (MACE) and bleeding rates in these antith-
rombotic groups were studied after one year.
Results: The mean age of patients who received DAPT was 814 years, whereas
those on TT had a mean age of 803 years. Patients receiving DAPT (n¼203, 52.5%)
were more likely to have a history of bleeding and infarction, while those on TT
(n¼184, 47.5%) had a past history of stroke. The 1-year MACE (15.7% vs 12.2%, HR
0.82, p¼0.548, for DAPT vs TT, respectively) and bleeding (9.4% vs 12.1%, HR
1.25, p¼0.413, for DAPT vs TT, respectively) rates were similar between the two
groups.
Conclusions: In contrast to consensus statements, elderly patients with AF under-
going PCI are most frequently treated with DAPT. Bleeding and ischemic compli-
cations remain substantial in this cohort irrespective of treatment.TCT-478
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Background: Development of deep venous thrombosis (DVT) in the setting of cancer
portends a poor prognosis. Low molecular weight heparins ( LMWH) are considered
the standard of care due to their superiority over warfarin. Additionally warfarin
resistance is common in cancer patients. The subcutaneous administration of LMWH
on a chronic basis is cumbersome and inconvenient. New oral anticoagulants (NOAC)
are promising drugs which can simplify long term care of cancer patients with DVT.
However little is known on their efﬁcacy in this setting. We therefore sought to
evaluate the role of NOAC in patients with cancer- related lower extremity (LE) DVT
who received rivaroxaban and apixaban following percutaneous endovenous inter-
vention (PEVI).
Methods: PEVI was performed in 50 patients with cancer who had developed
extensive symptomatic LE DVT. It was bilateral in 18 patients (36%). At the time of
DVT, 15 patients (30%) were on warfarin of whom 7 had therapeutic INR (64%).
PEVI was performed within 235 hours of admission. All patients received heparin
which was stopped after completion of PEVI. Rivaroxaban was initiated at 20 mg
daily and apixaban at 5 mg twice daily, 2 hours after PEVI, and continued indeﬁnitely.
Warfarin was stopped in all. The mean follow up was 154 months. The patients were
evaluated for mortality, recurrent VTE and bleeding during this period.racts/Pharmacotherapy - Chronic anticoagulants (warfarin and newer agents)
